AgingResearch.NewsJoin free

SIWA318H

SIWA318H has been studied in 1 paper since 2023: none in people yet, 1 in animals. The research so far is in animals. The newest paper, Oct 7, 2023: “Advanced glycation end product (AGE) targeting antibody SIWA318H is efficacious in preclinical models for pancreatic cancer”.

Intervention

1 paper studies it3 findingsUpdated

See all 1

None of its findings points the other way.

C, W, M, H: cells, worms or flies, mice, humans. Dark: independent labs found the same change there. Light: one lab or one study. Outline: nothing yet.

Company ties: findings with an author at a company, or from a paper whose competing-interests statement declares ties to one.

  • 1 lab in 1 country
  • Funders: National Cancer Institute and 2 more
  • 3 of 3 findings with company ties
  • Animals1

What did studies of SIWA318H find?

3

Studies of SIWA318H measured 3 outcomes; the most studied are cellular senescence (1 study), complete remission rate (1) and tumor growth (1).

Cellular senescence

downin mice1

1 study

  1. SIWA318H decreases cellular senescence in mice (p < 0.05).

    “Immunohistochemical analyses of the tumor tissues showed a significant decrease in senescent cells in the tumor microenvironment of SIWA318H treated mice compared to that of control treated mice (p < 0.05).”

    Animalsin the tumor microenvironment of pancreatic cancer xenograft micetumor microenvironment

    Advanced glycation end product (AGE) targeting antibody SIWA318H is efficacious in preclinical models for pancreatic cancer

    Scientific reports

More on Cellular senescence

Complete remission rate

upin mice1

1 study

  1. SIWA318H increases complete remission rate in mice (60% (high dose, p < 0.04) and 77.8% (low dose, p < 0.02) vs 6.7% control).

    “Moreover, a significant increase in complete remission (CR) rate was observed in mice receiving the high dose (60%, p < 0.04) or low dose (77.8%, p < 0.02) of SIWA318H treatment compared with control mice (6.7%).”

    Animalsin a humanized CD34+ NSG mouse xenograft model for pancreatic cancer

    Advanced glycation end product (AGE) targeting antibody SIWA318H is efficacious in preclinical models for pancreatic cancer

    Scientific reports

Tumor growth

downin mice1

1 study

  1. SIWA318H decreases tumor growth in mice (-68.8% (high dose) and -61.5% (low dose), ANOVA p < 0.002).

    “tumor growth was suppressed by 68.8% and 61.5% for the high and low dose regimens, respectively, when compared to the isotype antibody control (ANOVA p < 0.002).”

    Animalsin a humanized CD34+ NSG mouse xenograft model for pancreatic cancer3 weeks

    Advanced glycation end product (AGE) targeting antibody SIWA318H is efficacious in preclinical models for pancreatic cancer

    Scientific reports

Latest

Related